Shares of HeartCare-B (06609) surged more than 16% during the trading session. As of this writing, the stock is up 14.17%, currently trading at HK$47.06, with a turnover of HK$8.5008 million.

On July 21st, HeartCare-B issued an interim profit forecast for 2026. The company anticipates achieving revenue of no less than RMB 280 million for the first half of 2026, representing year-on-year growth exceeding 50.9%. Net profit is expected to be no less than RMB 60 million, while adjusted net profit is projected to be no less than RMB 70 million, marking an increase of at least 104.7% year-on-year, indicating a further enhancement in profitability.

During the reporting period, the company continued to advance its three core business segments: ischemic stroke, hemorrhagic stroke, and vascular closure. The clinical recognition and market penetration of its core products have steadily increased, driving stable growth in end-user demand. The growth in adjusted net profit is primarily attributed to a higher revenue contribution from high-margin products, leading to an overall improvement in gross margin compared to the same period last year, alongside enhanced operational efficiency.